• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

将表达 RNA 基因组学从针对细胞学不确定的甲状腺结节的手术决策扩展到针对转移性甲状腺癌的靶向治疗。

Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer.

机构信息

Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland.

Department of Radiology, The Johns Hopkins Hospital, Baltimore, Maryland.

出版信息

Cancer Cytopathol. 2019 Jun;127(6):362-369. doi: 10.1002/cncy.22132. Epub 2019 Apr 24.

DOI:10.1002/cncy.22132
PMID:31017745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6618055/
Abstract

The Afirma Genomic Sequencing Classifier (GSC) is a rule‐out test for malignancy/noninvasive follicular thyroid neoplasms with papillary‐like nuclear features among patients with Bethesda category III/IV nodules, whereas the complimentary Xpression Atlas provides genomic insights from a curated panel of 511 genes among GSC suspicious and Bethesda category V/VI nodules. Together, they facilitate personalized treatment decisions based on genomic insights derived from the transcriptome of the biopsied target and extend the diagnostic and therapeutic reach of cytopathologists and fine‐needle aspiration biopsy sample collection.

摘要

AfiRa 基因测序分类器（GSC）是一种排除恶性肿瘤/非侵袭性滤泡性甲状腺肿瘤的检测方法，适用于 Bethesda 分类法 III/IV 级结节的患者，且这些患者具有甲状腺乳头状核特征。而 Xpression Atlas 则通过对 GSC 可疑结节和 Bethesda 分类法 V/VI 级结节中的 511 个基因进行精选，提供基因组信息。这两种检测方法相辅相成，有助于根据活检目标转录组的基因组信息做出个性化的治疗决策，并扩大细胞病理学家的诊断和治疗范围，增加细针抽吸活检样本的采集。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/6618055/e0daf7c18eb3/CNCY-127-362-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/6618055/3128b723455a/CNCY-127-362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/6618055/e0daf7c18eb3/CNCY-127-362-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/6618055/3128b723455a/CNCY-127-362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/6618055/e0daf7c18eb3/CNCY-127-362-g002.jpg

相似文献

1
Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer.将表达 RNA 基因组学从针对细胞学不确定的甲状腺结节的手术决策扩展到针对转移性甲状腺癌的靶向治疗。
Cancer Cytopathol. 2019 Jun;127(6):362-369. doi: 10.1002/cncy.22132. Epub 2019 Apr 24.
2
Getting more out of molecular testing for indeterminate thyroid nodules.从甲状腺结节性质不明的分子检测中获取更多信息。
Cancer Cytopathol. 2019 Sep;127(9):555-556. doi: 10.1002/cncy.22129. Epub 2019 Jun 25.
3
Thyroid Nodules: Advances in Evaluation and Management.甲状腺结节：评估与管理的新进展。
Am Fam Physician. 2020 Sep 1;102(5):298-304.
4
Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.术前 RAS 或 BRAF K601E 检测在甲状腺结节手术指导中的作用
World J Surg. 2020 Jul;44(7):2264-2271. doi: 10.1007/s00268-020-05487-1.
5
Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules.应用细胞周期蛋白 D1 免疫染色和基因组分析的细胞学筛查系统对甲状腺结节诊断的临床影响。
BMC Cancer. 2019 Mar 18;19(1):245. doi: 10.1186/s12885-019-5452-4.
6
Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.甲状腺细胞学不确定结节患者肿瘤大小与组织学和临床结局的关系。
JAMA Otolaryngol Head Neck Surg. 2018 Sep 1;144(9):788-795. doi: 10.1001/jamaoto.2018.1070.
7
Digital image-assisted quantitative nuclear analysis improves diagnostic accuracy of thyroid fine-needle aspiration cytology.数字图像辅助定量核分析提高甲状腺细针抽吸细胞学诊断的准确性。
Cancer Cytopathol. 2019 Aug;127(8):501-513. doi: 10.1002/cncy.22120. Epub 2019 May 31.
8
miR-146b measurement in FNA to distinguish papillary thyroid cancer from benign thyroid masses.在细针穿刺抽吸活检（FNA）中检测微小RNA-146b（miR-146b）以鉴别甲状腺乳头状癌与甲状腺良性肿块。
Br J Biomed Sci. 2018 Jan;75(1):43-45. doi: 10.1080/09674845.2017.1347336. Epub 2017 Sep 22.
9
Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.甲状腺结节分子分析：Afirma Xpression Atlas 在 Afirma 基因组测序分类器可疑结果的结节中的临床应用。
Surgery. 2022 Jan;171(1):155-159. doi: 10.1016/j.surg.2021.08.058.
10
A large series of hyalinizing trabecular tumors: Cytomorphology and ancillary techniques on fine needle aspiration.大量透明小梁状肿瘤：细针吸取细胞学形态及辅助技术。
Cancer Cytopathol. 2019 Jun;127(6):390-398. doi: 10.1002/cncy.22139. Epub 2019 May 28.

引用本文的文献

1
XGBoost-based machine learning model combining clinical and ultrasound data for personalized prediction of thyroid nodule malignancy.基于XGBoost的机器学习模型结合临床和超声数据用于甲状腺结节恶性肿瘤的个性化预测
Front Endocrinol (Lausanne). 2025 Jul 29;16:1639639. doi: 10.3389/fendo.2025.1639639. eCollection 2025.
2
Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.端粒酶逆转录酶（TERT）启动子突变分析的验证。
J Clin Endocrinol Metab. 2024 Aug 13;109(9):2269-2273. doi: 10.1210/clinem/dgae134.
3
Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers.

本文引用的文献

1
Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms.许特耳细胞癌的识别：利用基因组测序和三种机器学习算法应对临床挑战
BMC Syst Biol. 2019 Apr 5;13(Suppl 2):27. doi: 10.1186/s12918-019-0693-z.
2
Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.对细胞学不确定的甲状腺结节的 Afirma 基因组测序分类器和基因表达分类器的独立比较。
Thyroid. 2019 May;29(5):650-656. doi: 10.1089/thy.2018.0726. Epub 2019 Mar 22.
3
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
甲状腺癌颈部复发细针穿刺抽吸物的下一代测序
Eur Thyroid J. 2024 Jan 1;13(1). doi: 10.1530/ETJ-23-0164.
4
Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities.甲状腺结节评估中的分子诊断：当前的应用和未来的机会。
Front Endocrinol (Lausanne). 2023 Feb 24;14:1101410. doi: 10.3389/fendo.2023.1101410. eCollection 2023.
5
Maximizing Small Biopsy Patient Samples: Unified RNA-Seq Platform Assessment of over 120,000 Patient Biopsies.最大化小活检患者样本：对超过12万份患者活检样本进行统一的RNA测序平台评估
J Pers Med. 2022 Dec 22;13(1):24. doi: 10.3390/jpm13010024.
6
Incorporation of a machine learning pathological diagnosis algorithm into the thyroid ultrasound imaging data improves the diagnosis risk of malignant thyroid nodules.将机器学习病理诊断算法纳入甲状腺超声成像数据可提高甲状腺恶性结节的诊断风险。
Front Oncol. 2022 Dec 8;12:968784. doi: 10.3389/fonc.2022.968784. eCollection 2022.
7
Artificial Intelligence for Pre-operative Diagnosis of Malignant Thyroid Nodules Based on Sonographic Features and Cytology Category.基于超声特征和细胞学分类的甲状腺恶性结节术前人工智能诊断。
World J Surg. 2023 Feb;47(2):330-339. doi: 10.1007/s00268-022-06798-1. Epub 2022 Nov 6.
8
External validation of AIBx, an artificial intelligence model for risk stratification, in thyroid nodules.用于甲状腺结节风险分层的人工智能模型AIBx的外部验证
Eur Thyroid J. 2022 Mar 8;11(2):e210129. doi: 10.1530/ETJ-21-0129.
9
A five-gene panel refines differential diagnosis of thyroid nodules.五基因检测 panel 可改善甲状腺结节的鉴别诊断。
J Clin Lab Anal. 2021 Sep;35(9):e23920. doi: 10.1002/jcla.23920. Epub 2021 Jul 28.
10
Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.Thyroseq v3、Afiirma GSC 和 microRNA 面板与术前诊断不确定甲状腺结节的先前分子检测的比较：系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 May 13;12:649522. doi: 10.3389/fendo.2021.649522. eCollection 2021.
多基因基因组分类器在具有不确定细胞学的甲状腺结节中的表现：一项前瞻性盲法多中心研究。
JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.
4
The association between the ultrasonography TIRADS classification system and surgical pathology among indeterminate thyroid nodules.超声 TI-RADS 分类系统与不确定甲状腺结节手术病理的相关性。
Surgery. 2019 Jan;165(1):69-74. doi: 10.1016/j.surg.2018.04.094. Epub 2018 Nov 8.
5
STATISTICAL COMPARISON OF AFIRMA GSC AND AFIRMA GEC OUTCOMES IN A COMMUNITY ENDOCRINE SURGICAL PRACTICE: EARLY FINDINGS.社区内分泌外科实践中 AFIRMA GSC 和 AFIRMA GEC 结果的统计学比较：初步发现。
Endocr Pract. 2019 Feb;25(2):161-164. doi: 10.4158/EP-2018-0395. Epub 2018 Nov 1.
6
Increased mortality and morbidity in patients with chronic hypoparathyroidism: A population-based study.慢性甲状旁腺功能减退症患者的死亡率和发病率增加：一项基于人群的研究。
Clin Endocrinol (Oxf). 2019 Feb;90(2):285-292. doi: 10.1111/cen.13895. Epub 2018 Nov 20.
7
Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS.在提高诊断准确性的同时减少不必要的甲状腺活检：走向“正确”的 TIRADS。
J Clin Endocrinol Metab. 2019 Jan 1;104(1):95-102. doi: 10.1210/jc.2018-01674.
8
Ultrasonography Classification of the American Thyroid Association for Predicting Malignancy in Thyroid Nodules >1cm with Indeterminate Cytology: A Prospective Study.美国甲状腺协会超声检查分类对预测细胞学检查结果不确定的直径>1cm甲状腺结节恶性风险的前瞻性研究
Horm Metab Res. 2018 Aug;50(8):597-601. doi: 10.1055/a-0655-3016. Epub 2018 Aug 6.
9
Factors Predicting Thyroid Malignancy in Fine Needle Aspiration Biopsy Specimens Classified as Atypia of Uncertain Significance/Follicular Lesion of Uncertain Significance.细针穿刺活检标本分类为意义不明确的非典型性/意义不明确的滤泡性病变时预测甲状腺恶性肿瘤的因素
Am Surg. 2018 Jul 1;84(7):1207-1213.
10
Thyroidectomy in older adults: an American College of Surgeons National Surgical Quality Improvement Program study of outcomes.老年患者的甲状腺切除术：美国外科医师学会国家外科质量改进计划的结局研究
J Surg Res. 2018 Sep;229:20-27. doi: 10.1016/j.jss.2018.03.057. Epub 2018 Apr 16.